MEDIPOST Co., Ltd. (KOSDAQ: 078160)

Market Cap	421.12B
Revenue (ttm)	69.86B
Net Income (ttm)	-10.82B
Shares Out	34.10M
EPS (ttm)	-332.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,749
Open	11,870
Previous Close	11,970
Day's Range	11,870 - 12,560
52-Week Range	5,450 - 15,180
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 27, 2025

About MEDIPOST

MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 308
• Stock Exchange: KOSDAQ
• Ticker Symbol: 078160

Financial Performance

In 2023, MEDIPOST's revenue was 68.64 billion, an increase of 6.92% compared to the previous year's 64.20 billion. Earnings were 5.84 billion, an increase of 90.31%.